Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients

Author:

Schlumberger M.1,Hitzel A.2,Toubert M. E.3,Corone C.4,Troalen F.1,Schlageter M. H.3,Claustrat F.5,Koscielny S.1,Taieb D.6,Toubeau M.78,Bonichon F.,Borson-Chazot F.59,Leenhardt L.10,Schvartz C.11,Dejax C.12,Brenot-Rossi I.13,Torlontano M.,Tenenbaum F.14,Bardet S.15,Bussière F.16,Girard J. J.17,Morel O.18,Schneegans O.19,Schlienger J. L.20,Prost A.21,So D.22,Archambeaud F.23,Ricard M.1,Benhamou E.1

Affiliation:

1. Institut Gustave Roussy and University Paris Sud (M.S., F.Tr., S.K., M.R., E.B.), Villejuif, France

2. Centre Henri Becquerel (A.H.), Rouen, France

3. Hôpital Saint Louis (M.E.T., M.H.S.), AP-HP, Paris, France

4. Centre René Huguenin (C.C.), Saint Cloud, France

5. Hospices Civils de Lyon (F.C., F.B.-C.), Lyon, France

6. Hopital La Timone (D.T.), Marseille, France

7. Department of Hôpital de San Giovanni Rotondo (M.T.), Italy

8. Centre Georges François Leclerc (M.T.), Dijon, France

9. Institut Bergonié (F.Bo.), Bordeaux, France

10. Hôpital de la Pitié (L.L.), AP-HP, Paris, France

11. Institut Jean Godinot (C.S.), Reims, France

12. Centre Jean Perrin (C.D.), Clermont Ferrand, France

13. Institut Paoli Calmettes (I.B.-R.), Marseille, France

14. Hôpital Cochin (F.Te.), AP-HP, Paris, France

15. Department of Centre François Baclesse (S.B.), Caen, France

16. Department of Centre Lacassagne (F.Bu.), Nice, France

17. Department of Hôpital Bretonneau (J.J.G.), Tours, France

18. Department of Centre Paul Papin (O.M.), Angers, France

19. Department of Centre Paul Strauss (O.S.), Strasbourg, France

20. Hôpital Hautepierre (J.L.S.), Strasbourg, France

21. Hôpital du Mans (A.P.), Le Mans, France

22. Hôpital de Thionville (D.S.), Thionville, France

23. Hôpital de Limoges (F.A.), Limoges, France

Abstract

Abstract Background: Serum thyroglobulin (Tg) is the marker of differentiated thyroid cancer after initial treatment and TSH stimulation increases its sensitivity for the diagnosis of recurrent disease. Aim: The goal of the study is to compare the diagnostic values of seven methods for serum Tg measurement for detecting recurrent disease both during L-T4 treatment and after TSH stimulation. Methods: Thyroid cancer patients who had no evidence of persistent disease after initial treatment (total thyroidectomy and radioiodine ablation) were studied at 3 months on L-T4 treatment (Tg1) and then at 9–12 months after withdrawal or recombinant human TSH stimulation (Tg2). Sera with anti-Tg antibodies or with an abnormal recovery test result were excluded from Tg analysis with the corresponding assay. The results of serum Tg determination were compared to the clinical status of the patient at the end of follow-up. Results: Thirty recurrences were detected among 944 patients. A control 131I total body scan had a low sensitivity, a low specificity, and a low clinical impact. Assuming a common cutoff for all Tg assays at 0.9 ng/ml, sensitivity ranged from 19–40% and 68–76% and specificity ranged from 92–97% and 81–91% for Tg 1 and Tg2, respectively. Using assays with a functional sensitivity at 0.2–0.3 ng/ml, sensitivity was 54–63% and specificity was 89% for Tg1. Using the two methods with a lowest functional sensitivity at 0.02 and 0.11 ng/ml resulted in a higher sensitivity for Tg1 (81% and 78%), but at the expense of a loss of specificity (42% and 63%); finally, for these two methods, using an optimized functional sensitivity according to receiver operating characteristic curves at 0.22 and 0.27 ng/ml resulted in a sensitivity at 65% and specificity at 85–87% for Tg1. Conclusion: Using an assay with a lower functional sensitivity may give an earlier indication of the presence of Tg in the serum on L-T4 treatment and may be used to study the trend in serum Tg without performing any TSH stimulation. Serum Tg determination obtained after TSH stimulation still permits a more reliable assessment of cure and patient’s reassurance.

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference27 articles.

1. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma.;Travagli;J Clin Endocrinol Metab,1998

2. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.;Durante;J Clin Endocrinol Metab,2006

3. Papillary and follicular thyroid carcinoma.;Schlumberger;N Engl J Med,1998

4. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.;Eustatia-Rutten;Clin Endocrinol,2004

5. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.;Haugen;J Clin Endocrinol Metab,1999

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3